Luxembourg Center for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Curr Neurol Neurosci Rep. 2022 Aug;22(8):427-440. doi: 10.1007/s11910-022-01207-5. Epub 2022 Jun 8.
Neuroinflammation plays a significant role in Parkinson's disease (PD) etiology along with mitochondrial dysfunction and impaired proteostasis. In this context, mechanisms related to immune response can act as modifiers at different steps of the neurodegenerative process and justify the growing interest in anti-inflammatory agents as potential disease-modifying treatments in PD. The discovery of inherited gene mutations in PD has allowed researchers to develop cellular and animal models to study the mechanisms of the underlying biology, but the original cause of neuroinflammation in PD is still debated to date.
Cell autonomous alterations in neuronal cells, including mitochondrial damage and protein aggregation, could play a role, but recent findings also highlighted the importance of intercellular communication at both local and systemic level. This has given rise to debate about the role of non-neuronal cells in PD and reignited intense research into the gut-brain axis and other non-neuronal interactions in the development of the disease. Whatever the original trigger of neuroinflammation in PD, what appears quite clear is that the aberrant activation of glial cells and other components of the immune system creates a vicious circle in which neurodegeneration and neuroinflammation nourish each other. In this review, we will provide an up-to-date summary of the main cellular alterations underlying neuroinflammation in PD, including those induced by environmental factors (e.g. the gut microbiome) and those related to the genetic background of affected patients. Starting from the lesson provided by familial forms of PD, we will discuss pathophysiological mechanisms linked to inflammation that could also play a role in idiopathic forms. Finally, we will comment on the potential clinical translatability of immunobiomarkers identified in PD patient cohorts and provide an update on current therapeutic strategies aimed at overcoming or preventing inflammation in PD.
神经炎症在帕金森病 (PD) 的发病机制中起着重要作用,与线粒体功能障碍和蛋白质稳态受损有关。在这种情况下,与免疫反应相关的机制可以作为神经退行性过程不同步骤的修饰物,并证明了人们对抗炎药物作为 PD 潜在疾病修饰治疗的兴趣日益增加。PD 中遗传性基因突变的发现使研究人员能够开发细胞和动物模型来研究潜在生物学的机制,但 PD 中神经炎症的最初原因至今仍存在争议。
神经元细胞的自主改变,包括线粒体损伤和蛋白质聚集,可能起作用,但最近的发现也强调了细胞间通讯在局部和全身水平的重要性。这引发了关于非神经元细胞在 PD 中的作用的争论,并重新激起了对肠道-大脑轴和疾病发展中其他非神经元相互作用的强烈研究。无论 PD 中神经炎症的最初触发因素是什么,很明显的是,胶质细胞和免疫系统的其他成分的异常激活在神经退行性变和神经炎症之间形成了一个恶性循环。在这篇综述中,我们将提供 PD 中神经炎症的主要细胞改变的最新总结,包括由环境因素(例如肠道微生物组)和受影响患者的遗传背景引起的改变。从家族性 PD 形式提供的教训出发,我们将讨论与炎症相关的病理生理机制,这些机制也可能在特发性 PD 中起作用。最后,我们将对 PD 患者队列中鉴定的免疫生物标志物的潜在临床转化性进行评论,并提供当前旨在克服或预防 PD 中炎症的治疗策略的最新信息。